麻豆传媒

Gurdeep is a Senior Lecturer in Health Economics at 麻豆传媒 where he is co-lead of the health economics group. He is also the health economics lead for both the and the . He has a strong academic background in the fields of economic evaluation, evidence synthesis, and the evaluation of diagnostic tests with expertise built on over 15 years of experience across a range of Institutions. Gurdeep works nationally and internationally with collaborators from a range of different backgrounds including those with academic, non-academic, and clinical areas of expertise. He is also a Deputy Editor for the , the official journal of Health Technology Assessment International () which is the society championing the equitable and responsive use of cutting-edge methods in HTA worldwide.

Gurdeep’s research focuses on the robust and timely evaluation of health technologies across a range of settings and disease areas providing evidence on whether such technologies deliver value for money. His work involves the development and application of methods used in evidence generation as well as the appraisal of existing evidence through established health technology appraisal approaches. In particular, Gurdeep is interested in the development and application of early economic modelling within adaptive trial designs alongside the use of real-world evidence. This is a growing area of research given the push towards quicker decision making in the face of the existing limitations of lengthy evidence generation methodology.

As a member of the senior management team for the large Health Economics Group he has direct oversight of all teaching activities. Gurdeep is also involved in the strategic decision making required to run an academic unit including current and future workload planning alongside grant development. In addition, he currently directly line-manages a team of five researchers which involves staff training, development, welfare, career progression, and oversight for project delivery. Gurdeep also has oversight for another eight researchers, 6 PhD students, 2 MD students and 2 pre-doctoral fellows.

Prior to joining 麻豆传媒, he was a Lecturer in Health Economics at the University of Leeds within the Academic Unit of Health Economics, Deputy Lead for the Health Economics Theme for the NIHR Leeds In Vitro Diagnostics Co-operative (NIHR Leeds MIC), and the Director of the University of Leeds . At the University of Leeds Gurdeep was also the co-lead for the Athena SWAN Self-Assessment Team within the Leeds Institute of Health Sciences when Leeds became the first Medical School in the country to be awarded the .

Currently, Gurdeep is a member of the . He has published over 50 peer-reviewed articles and been involved in grant awards totalling more £50m in the fields of economic evaluation, evidence synthesis, diagnostics, and health technology evaluation. His commitment to teaching includes supervision of undergraduate and post-graduate students as well as being the teaching lead for the health economics group and the lead for the Health Economics module (HSC8027) on the Masters in Public Health. This involves curriculum development, content delivery, and the design of student assessment. Gurdeep also sits on both the Public Health Board of Studies and Board of Examiners.

Key research interests are:

·       Economic evaluation as part of randomised controlled trials and Health Technology Assessments for national and international agencies

·       Use of economic evaluation techniques in the design of complex interventions and health technologies including earlier use of modelling to guide technology development

·       Identification and exploration of methods to improve the efficiency of economic evaluation research in challenging areas such as rare diseases, diagnostics, pharmacogenomics, digital health and artificial intelligence

Area of expertise:

·       Economic evaluation

·       Health technology assessment

·       Health economics

I would be interested in hearing from prospective PhD students if they have research interests in any of the areas mentioned above. 

• Articles

  • Uteh CO, Johnson EE, Robinson T, Moradi N, Inskip A, Beyer FR, Thomson K, Sagoo GS. . Pharmacoeconomics 2025, 43, 469-472.
  • Johnson EE, Orozco Leal G, Still M, O'Connor N, Jayachandran L, Robinson T, Meader N, Kenny RPW, Wallace SA, Garcia Gonzalez-Moral S, Vale L, Parker R, Rice S, Sagoo GS, Pearson F. . International Journal of Technology Assessment in Health Care 2025, 41(1), e64.
  • Sagoo GS, Clement ND, Gil-Rojas Y, Bhattarai N, Galloway S, Baron JB, Smith K, Weir DJ, Deehan DJ. . Bone and Joint Open 2025, 6(6), 658-666.
  • Moradi N, O'Connor N, Thomson KH, Shabaninejad H, Sotire T, Still M, Fernandez-Garcia C, Wallace SA, Williams O, Vale L, Sagoo GS. . PharmacoEconomics 2024, 42, 913-917.
  • Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J, Velikova G, Gallagher FA, Smith A, Howard H, Mason E, Katona E, Silva S, Collinson M, Rodwell S, Danson S. . BMC Cancer 2021, 21, 761.
  • Sutton AJ, Sagoo GS, Jackson L, Fisher M, Hamilton-Fairley G, Murray A, Hill A. Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules. PLoS ONE 2020, 15(9 September), -.
  • Melhuish A, Vargas-Palacios A, Yaziji N, Selfridge J, Pisavadia M, Sagoo GS, Minton J. Cost evaluation of point-of-care testing for community-acquired influenza in adults presenting to the emergency department. Journal of Clinical Virology 2020, 129, -.
  • Abel L, Shinkins B, Smith A, Sutton AJ, Sagoo GS, Uchegbu I, Allen AJ, Graziadio S, Moloney E, Yang Y, Hall P. . Medical Decision Making 2019, 39(7), 857-866.
  • Sagoo GS, Mohammed S, Barton G, Norbury G, Ahn JW, Ogilvie CM, Kroese M. Cost Effectiveness of Using Array-CGH for Diagnosing Learning Disability. Applied Health Economics and Health Policy 2015, 13(4), 421-432.
  • Moorthie S, Cameron L, Sagoo GS, Bonham JR, Burton H. Systematic review and meta-analysis to estimate the birth prevalence of five inherited metabolic diseases. Journal of Inherited Metabolic Disease 2014, 37(6), 889-898.

• Note

  • Pokorska-Bocci A, Kroese M, Sagoo GS, Hall A, Burton H. Personalised medicine in the UK: Challenges of implementation and impact on healthcare system. Genome Medicine 2014, 6(4), -.

• Report

  • Thomson K, O'Connor N, Shabaninejad H, Sotire T, Still M, Moradi N, Fernandez-Garcia C, Wallace SA, Williams O, Vale L, Sagoo G. . Manchester: National Institute for Health and Care Excellence, 2024. Highly Specialised Technologies Guidance.

• Reviews

  • Abdul-Aziz S, Bhattarai N, Vale L, Sagoo GS, Mukhopadhyay A. . Gynecologic Oncology Reports 2025, 57, 101680.
  • Sagoo GS, Robinson T, Coughlan D, Meader N, Rice S, Vale L. . Expert Review of Pharmacoeconomics and Outcomes Research 2023, 23(10), 1177-1183.